Last Updated on October 9, 2024 by The Health Master
After a GMP inspection of the company’s Plant II (Sterile Facility) and Plant III (OSD Facility) in Goa, the United States Food and Drug Administration (USFDA) has issued four observations, according to an announcement from Indoco Remedies Limited in Mumbai.
The inspection was conducted from 20th February, 2023 to 28th February, 2023.
Four (4) observations on Form 483 from the USFDA have been made, and they will be resolved within the allotted time.
“e believe that this will not have an impact on the supplies and the existing revenues from these Facilities,” Indoco Remedies stated in a BSE filing.
When an investigator(s) has(have) observed any conditions that in their opinion may constitute violations of the Food, Drug, and Cosmetic (FD&C) Act and related Acts, an USFDA Form 483 is issued to firm management at the conclusion of an inspection.
“The Company is committed to maintaining compliances with cGMP quality standards across all of our facilities at all times,” Indoco continued.
The USFDA issued nine observations following a GMP inspection at the company’s Solid Oral Formulation Facility (Plant 1) in Goa, according to a previous report by Medical Dialogues Team.
Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharmaceutical company that manufactures and markets Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
The company has 9 manufacturing facilities, out of which, 6 are for finished dosages and 3 for APIs, supported by a state-of-the-art R&D centre at Rabale, Navi Mumbai and a Clinical Research Organisation at Hyderabad.
Its manufacturing facilities have been approved by various regulatory authorities such as:
- USFDA,
- UK-MHRA,
- TGA-Australia,
- SAHPRA-South Africa,
- NDA-Uganda,
- TMDA-Tanzania,
- MOH-Ukraine,
- PPB-Kenya,
- DPML-Ivory Coast, etc.
Indoco offers complete solutions, including product development, manufacture and supply of Finished Dosages, APIs and Intermediates to generic companies worldwide.
The company has a large basket of products backed by ANDAs / eCTD Dossiers and Drug Master Files (DMFs).
USFDA issues Form 483 with 8 observations to Cipla for Pithampur facility
USFDA issues Form 483 with 2 observations to Laurus Labs for Visakhapatnam facility
USFDA issues 2 observations to Natco Pharma for Vizag facility
USFDA issues Form 483 with zero observation to Solara Active Pharma Sciences Vizag Facility
USFDA issues Form 483 with 9 observations to Indoco Remedies, Goa
USFDA issues Form 483 with 8 observations to Jubilant
Attack on doctors: OPD services shut across the state as medicos protest
NPPA fixed Ceiling price of 1 scheduled formulation: February 2023
USFDA gives nod for Docetaxel Injection USP
Private hospital fined Rs 1 lakh for littering ‘Biomedical Waste’
Govt revises guidelines for PLI scheme for Medical Devices
Spurious drugs worth Rs 2 lakh seized, distributor arrested
NPPA revised Ceiling price of 80 scheduled formulations: February 2023
India aims to be the world’s most respected drugs regulator: HM
Duties and responsibilities of QA person in Pharma Industry
NPPA fixed retail price of 74 formulations: February 2023
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
